Neoplasms

Blood and Lymph Conditions

Immune System Diseases

All Conditions

Nervous System Diseases

Gland and Hormone Related Diseases

Symptoms and General Pathology

Musculoskeletal Diseases

Eye Diseases

Rare Diseases

Lymphoma

Pituitary Diseases

Recurrence

Glioblastoma

Glioma

Brain Neoplasms

Medulloblastoma

Sarcoma, Ewing

Neuroectodermal Tumors, Primitive, Peripheral

Meningioma

Germinoma

Astrocytoma

Pituitary Neoplasms

Ependymoma

Craniopharyngioma

Adamantinoma

Oligodendroglioma

Chordoma

Neoplasms, Neuroepithelial

Optic Nerve Glioma

Glioma, Subependymal

Disease Attributes

Central Nervous System Neoplasms

Nervous System Neoplasms

Brain Diseases

Central Nervous System Diseases

Lymphosarcoma

Germ Cells Tumors

Central Nervous System Germinoma

Brain Tumor, Childhood

Primary Central Nervous System Lymphoma

Anaplastic Astrocytoma

Pilocytic Astrocytoma

Subependymoma

Antineoplastic Agents

Dermatologic Agents

All Drugs and Chemicals

Central Nervous System Depressants

Dihematoporphyrin Ether

Trioxsalen

Hematoporphyrin Derivative

Ether

Photosensitizing Agents

Photofrin (porfimer sodium) photodynamic therapy.

Intravenous (IV) Photofrin

This is a dose escalation study. Patients will receive Photofrin via an IV infusion approximately 24 hours prior to their tumor resection surgery and Photodynamic Therapy (PDT). Patients will be light sensitive immediately upon receiving the Photofrin and must observe photosensitivity \& light precautions for a minimum of 30 days after the infusion.

Photodynamic Therapy (PDT)

After tumor resection, an optical fiber will be placed in the approximate center of the surgical cavity. Intralipid will be infused into the open tumor cavity while PDT is performed. The Intralipid will diffuse the light and ensure uniform delivery. Photoactivation of Photofrin is controlled by the total light dose delivered over the treatment time.

Photofrin (porfimer sodium) & photodynamic therapy.

Harry T Whelan, MD

Jeff Knipstein, MD

The goal of this proposal is to evaluate a new Photodynamic Therapy (PDT) modification which could revolutionize the treatment of brain tumors in children and adults. There are currently few cases published involving the use of PDT in infratentorial (in the posterior fossa) brain tumors in general and specifically those occurring in children. The investigators propose to test a technique, for the first time in the U.S., that demonstrated in Australian adult glioblastoma patients dramatic long-term, survival rates of 57% (anaplastic astrocytoma) and 37% (glioblastoma multiforme). These results are unprecedented in any other treatment protocol.

Photodynamic therapy (PDT) is a paradigm shift in the treatment of tumors from the traditional resection and systemic chemotherapy methods. The principle behind photodynamic therapy is light-mediated activation of a photosensitizer that is selectively accumulated in the target tissue, causing tumor cell destruction through singlet oxygen production. Therefore, the photosensitizer is considered to be the first critical element in PDT procedures, and the activation procedure is the second step. The methodology used in this proposal utilizes more intensive laser light and larger Photofrin photosensitizer doses than prior PDT protocols in the U.S. for brain tumor patients. The PDT will consist of photoillumination at 630 nm beginning at the center of the tumor resection cavity, and delivering a total energy of 240 J cm-2. The investigators feel that the light should penetrate far enough into the tissue to reach migrating tumor cells, and destroy these cells without harming the healthy cells in which they are dispersed.

The investigators will be testing the hypothesis that pediatric subjects with progressive/recurrent malignant brain tumors undergoing PDT with increased doses of Photofrin® and light energy than were used in our previous clinical study will show better progression free survival (PFS) and overall survival (OS) outcomes. PDT will also be effective against infratentorial tumors. The specific aims include determining the maximum tolerable dose (MTD) of Photofrin in children and looking for preliminary effectiveness trends.

Photodynamic Therapy (PDT) for Recurrent Pediatric Brain Tumors

Photodynamic Therapy (PDT) for Poor Prognosis Recurrent/Refractory Malignant Brain Tumors - A Phase I Study

MTD is defined as the Photofrin® dose that precedes the dose level used with a subgroup of subjects that exhibits a greater than 33% DLT occurrence.

DLT is defined as any of the following events with reasonable possibility to be attributable to the experimental intervention:

1. Neurotoxicity: defined as a decline in neurological function manifest within 1 week of PDT and persistent to 4 weeks post-PDT. Adverse events of neurologic function of grade 4, or a level change from grade 1 to grade 3, within this period will constitute neurotoxicity for this study. The CTCAE V4.02 will be used.
2. Photosensitivity: defined as a photosensitivity adverse event (CTCAE category dermatology/skin) of grade 4 occurring within the same period.
3. Ocular sensitivity: Photofrin®-induced ocular sensitivity is defined as a photophobia adverse event (CTCAE category ocular/visual) of grade 4 within the same period.
4. Any other toxicity of CTCAE grade 4 or higher within the same period.

To preliminarily define the antitumor activity of Photofrin and laser light activation within the confines of a Phase 1 Study. We will follow progression free survival and overall survival for 3 years post PDT treatment.

Pinnacle Biologics Inc.

Bleser Professor of Neurology

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Photodynamic Therapy (PDT) for Recurrent Pediatric Brain Tumors	NCT01682746	Brain Tumor, Re...	Photofrin (porf...	6 Months - 18 Years	Medical College of Wisconsin
Photodynamic Therapy (PDT) for Recurrent Pediatric Brain Tumors	NCT01682746	Brain Tumor, Re...	Photofrin (porf...	6 Months - 18 Years	Medical College of Wisconsin
Photodynamic Therapy (PDT) for Recurrent Pediatric Brain Tumors	NCT01682746	Brain Tumor, Re...	Photofrin (porf...	6 Months - 18 Years	Medical College of Wisconsin

Spots Global Cancer Trial Database for photofrin (porfimer sodium) & photodynamic therapy.